Careprost (Bimatoprost Ophthalmic 0.03%)
Clinical guidance, bioequivalence criteria, and verified partner dispensing standards for Careprost (Bimatoprost Ophthalmic 0.03%). Reviewed by board-certified internal medicine and clinical pharmacotherapy specialists.
📖 Peer-Reviewed Clinical Monograph1. Pharmacological Profile & Executive Summary
Synthetic prostamide analog clinically proven to extend eyelash follicle growth phase (anagen), increasing lash length, thickness, and dark pigmentation.
Dermatology & Retinoids • Careprost (Bimatoprost Ophthalmic 0.03%)
2. Human Pharmacokinetic Matrix
| Pharmacokinetic Parameter | Clinical Metric | Therapeutic Significance |
|---|---|---|
| Peak Plasma Time (Tmax) | Local dermal follicular transit | Determines latency from ingestion to peak pharmacological onset. |
| Elimination Half-Life (T½) | 45 minutes systemic clearance | Governs duration of action and steady-state dosing intervals. |
| Peak Concentration (Cmax) | <0.1 ng/mL | Maximum observed systemic concentration in human plasma. |
| Bioavailability & Food Interaction | Negligible systemic transit | Defines oral bioavailability and dietary lipid dependency. |
| Plasma Protein Binding | 88% | Governs free circulating drug fraction available for receptor binding. |
| Volume of Distribution (Vd) | 0.67 L/kg | Reflects tissue and lipid compartment penetration. |
| Hepatic Metabolism | Hydrolysis to active free acid | Primary enzymatic clearance and CYP pathways. |
| Elimination / Excretion | 67% urine, 25% feces | Renal vs biliary/fecal excretion balance. |
3. Evidence-Based Clinical Dosing Protocols
Daily / Baseline Regimen
Apply one single drop along upper eyelid margin at eyelash base once nightly.
On-Demand / Titration Regimen
Nightly application for 12–16 weeks.
Do not apply directly inside eyes or to lower eyelid.
4. Pharmacokinetic Drug-Drug Interaction Matrix
| Interacting Agent / Class | Severity Tier | Clinical Mechanism & Management Strategy |
|---|---|---|
| Prostaglandin Eyedrops | Precaution | May alter intraocular pressure in glaucoma. |
5. Adverse Reaction Profile & Clinical Incidence Rates
| Adverse Reaction | Incidence Rate | Physiological Mechanism & Mitigation Strategy |
|---|---|---|
| Conjunctival Redness | 4% | If solution enters eye. |
| Eyelid Margin Darkening | 2% | Reversible pigmentation. |
6. Patient Administration & Safe Usage Guidelines
Remove contact lenses before application. Apply strictly to upper eyelid base.
7. Frequently Asked Clinical Questions
How does Careprost compare to Allergan Latisse?
Careprost contains identical Bimatoprost 0.03% in sterile isotonic solution, offering bioequivalent results at 80% lower cost.
When are full eyelash results visible?
Initial growth starts at week 4; full length, density, and darkness peak at week 16.
Verified Telehealth Access Standards for Careprost (Bimatoprost Ophthalmic 0.03%)
Our clinical editorial board audits certified partner telehealth dispensaries to guarantee authentic WHO-GMP manufacturing, analytical batch testing, and physician-supervised asynchronous consultation.
Peer-Reviewed Scientific Citations & FDA References
- Fagien S, et al. Bimatoprost 0.03% for eyelash growth. Aesthet Surg J. 2013;33(5):738-745.